Donald Selph, MD
Internal Medicine · Eastman, GANPI 1427163344
Payments from drug & device makers
Across 129 payments — averaging $25.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$643
- Welch Allyn$643
- Novo Nordisk$440
- AstraZeneca$400
- Boehringer Ingelheim$223
- Johnson & Johnson$203
- plus $798 from 19 others
What the payments were for
- Food & beverage$2,05861%
- Education$60%
- Other$1,28638%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 1 | $643 |
| Welch Allyn | 1 | $643 |
| Novo Nordisk | 27 | $440 |
| AstraZeneca | 26 | $400 |
| Boehringer Ingelheim | 13 | $223 |
| Johnson & Johnson | 13 | $203 |
| AbbVie(2 entities) | 7 | $114 |
| Sunovion Pharmaceuticals Inc. | 5 | $93 |
| E.r. Squibb & Sons, L.L.C. | 2 | $86 |
| Pfizer | 5 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $60 |
| Lilly USA, LLC | 4 | $55 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| Abbott | 2 | $47 |
| Amgen | 3 | $40 |
| Esperion Therapeutics, Inc. | 3 | $39 |
| Merck | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Novartis | 1 | $17 |
| Sanofi | 1 | $16 |
| Bayer | 1 | $14 |
| GSK | 1 | $14 |
| Circassia Inc. | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NONE$643
How this compares
$3,350 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 311 | $232,395 |
| OzempicSemaglutide | 133 | $172,816 |
| MounjaroTirzepatide | 133 | $161,612 |
| JardianceEmpagliflozin | 165 | $147,167 |
| FarxigaDapagliflozin Propanediol | 155 | $132,103 |
| EntrestoSacubitril/Valsartan | 94 | $83,147 |
| XareltoRivaroxaban | 75 | $61,452 |
| LinzessLinaclotide | 94 | $49,313 |
| Tresiba Flextouch U-200Insulin Degludec | 49 | $38,752 |
| Tresiba Flextouch U-100Insulin Degludec | 53 | $37,794 |
| TrulicityDulaglutide | 39 | $36,236 |
| JanuviaSitagliptin Phosphate | 47 | $26,039 |
| VascepaIcosapent Ethyl | 47 | $22,135 |
| Risperdal ConstaRisperidone Microspheres | 20 | $19,698 |
| Repatha SureclickEvolocumab | 30 | $16,360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $80 | $236,940326 claims |
| Lilly USA, LLCMounjaro, Trulicity | $55 | $197,848172 claims |
| Novo NordiskOzempic | $440 | $172,816133 claims |
| Boehringer IngelheimJardiance | $223 | $147,167165 claims |
| AstraZenecaFarxiga, Brilinta | $400 | $145,424176 claims |
| NovartisEntresto | $17 | $83,14794 claims |
| Johnson & JohnsonXarelto, Risperdal Consta | $203 | $81,14995 claims |
| AbbVieLinzess | $114 | $49,31394 claims |
| GSKShingrix, Arexvy, Anoro Ellipta | $14 | $28,051103 claims |
| MerckJanuvia | $19 | $26,03947 claims |
| Esperion Therapeutics, Inc.Nexlizet | $39 | $10,94418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Eastman
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.